Details : The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Brand Name : XEN1101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 04, 2023
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
Details : The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Brand Name : XEN1101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 29, 2023
Xenon Pharmaceuticals Announces Proposed Public Offering
Details : The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Brand Name : XEN1101
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 29, 2023
Lead Product(s) : XEN1101
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : XEN1101 is a differentiated Kv7 potassium channel opener which is being evaluated under phase 2 clinical trials for the treatment of major depressive disorder (MDD).
Brand Name : XEN1101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 27, 2023
Lead Product(s) : XEN1101
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : XEN1101 is a differentiated Kv7 potassium channel opener administered as an adjunctive treatment for adult patients with focal epilepsy,being developed for the treatment of epilepsy and major depressive disorder.
Brand Name : XEN1101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 03, 2022
Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program
Details : New XEN1101 Phase 2b X-TOLE sub-group analysis demonstrates statistically significant efficacy results at all doses at Week 1, differentiating XEN1101 with rapid onset to seizure reduction.
Brand Name : XEN1101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2022
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA
Details : The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the DBP of XEN1101 compared to placebo.
Brand Name : XEN1101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 21, 2022
Lead Product(s) : XEN1101
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : XEN1101, a KCNQ channel opener, has been studied in Phase 2b clinical trial in adult patients demonstrated compelling efficacy results, with a statistically significant and dose-dependent reduction from baseline in monthly focal seizure frequency when co...
Brand Name : XEN1101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 03, 2022
Lead Product(s) : XEN1101
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : XEN1101, a differentiated Kv7 potassium channel modulator – administered as adjunctive treatment in adult patients with focal epilepsy.
Brand Name : XEN1101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 04, 2021
LOOKING FOR A SUPPLIER?
Reset All
